Development and evaluation of compounds for imaging of β-amyloid plaque by means of positron emission tomography

  • Gjermund Henriksen
  • Behrooz H. Yousefi
  • Alexander Drzezga
  • Hans-Jürgen Wester



The proof of concept for in vivo targeting of β-amyloid plaques (Aβ) in patients with Alzheimer’s disease (AD) by means of nuclear imaging methods has been shown in recent clinical studies.


For positron emission tomography (PET), the five compounds [11C]PIB, 3′[18F]FPIB, [18F]FDDNP, [11C]SB-13 and [18F]F-SB-13 have been developed by a formal charge neutralisation of agents used for staining of AD brain post mortem.


In AD-patients, these compounds have been shown to possess a selective uptake in the brain regions known to have a high Aβ-load. Progress towards tracers with proportionality between tracer uptake and quantity of Aβ-load, of use for longitudinal studies of AD patients, is addressed in the current development of Aβ-tracers.


Despite the extensive information on the structure–affinity relationship of several Aβ-binding compounds, data on the regional brain binding kinetics—beyond uptake in healthy rodents—have been obtained only for a few compounds. Recent results indicate that PET-imaging of Aβ-deposits in transgenic rodent models of AD is feasible which may be valuable for a more relevant preclinical evaluation of Aβ-tracers.


Alzheimer’s disease Amyloid plaque Nuclear imaging PET SPECT 



neurofibrillary tangles


frontotemporal lobar degeneration


progressive supranuclear palsy


  1. 1.
    Drzezga A, Grimmer T, Peller M, Wermke M, Siebner H, Rauschecker JP, et al. Impaired cross-modal inhibition in Alzheimer disease. PLoS Med. 2005;2:e288.PubMedCrossRefGoogle Scholar
  2. 2.
    Drzezga A, Grimmer T, Riemenschneider M, Lautenschlager N, Siebner H, Alexopoulus P, et al. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. J Nucl Med. 2005;46:1625–32.PubMedGoogle Scholar
  3. 3.
    Martins RN, Robinson PJ, Chleboun JO, Beyreuther K, Masters CL. The molecular pathology of amyloid deposition in Alzheimer’s disease. Mol Neurobiol. 1991;5:389–98.PubMedCrossRefGoogle Scholar
  4. 4.
    Beyreuther K, Masters CL. Amyloid precursor protein (APP) and beta A4 amyloid in the etiology of Alzheimer’s disease: precursor–product relationships in the derangement of neuronal function. Brain Pathol. 1991;1:241–51.PubMedCrossRefGoogle Scholar
  5. 5.
    Klunk WE, Debnath ML, Pettegrew JW. Development of small molecule probes for the beta-amyloid protein of Alzheimer’s disease. Neurobiol Aging. 1994;15:691–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Klunk WE, Debnath ML, Pettegrew JW. Chrysamine-G binding to Alzheimer and control brain: autopsy study of a new amyloid probe. Neurobiol Aging. 1995;16:541–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Dezutter NA, Dom RJ, De Groot TJ, Bormans GM, Verbruggen AM. 99mTc-MAMA-chrysamine G, a probe for beta amyloid protein of Alzheimer’s disease. Eur J Nucl Med. 1999;26:1392–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Styren SD, Hamilton RL, Styren GC, Klunk WE. X-34, a fluorescent derivative of Congo red: a novel histochemical stain for Alzheimer’s disease pathology. J Histochem Cytochem. 2000;48:1223–32.PubMedGoogle Scholar
  9. 9.
    Klunk WE, Bacskai BJ, Mathis CA, Kajdasz ST, McLellan ME, Frosch MP, et al. Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J Neuropathol Exp Neurol. 2002;61:797–805.PubMedGoogle Scholar
  10. 10.
    Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem. 2003;46:2740–54.PubMedCrossRefGoogle Scholar
  11. 11.
    Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging Brain Amyloid in Alzheimer’s Disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306–19.PubMedCrossRefGoogle Scholar
  12. 12.
    Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer’s disease. Brain. 2006;129:2856–66.PubMedCrossRefGoogle Scholar
  13. 13.
    Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab. 2005;25:1528–47.PubMedCrossRefGoogle Scholar
  14. 14.
    Kemppainen NM, Aalto S, Wilson IA, Nagren K, Helin S, Bruck A, et al. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology. 2007;68:1603–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2007 May 10; PMID: 17499392.Google Scholar
  16. 16.
    Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, et al. inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 2006;59:512–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Price JL, Morris JC. Tangles and plaques in nondemented aging and “preclinical” Alzheimer’s disease. Ann Neurol. 1999;45:358–68.PubMedCrossRefGoogle Scholar
  18. 18.
    Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446–52.PubMedCrossRefGoogle Scholar
  19. 19.
    Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, Lu X, et al. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med. 2005;46:1959–72.PubMedGoogle Scholar
  20. 20.
    Zhou Y, Resnick SM, Ye W, Fan H, Holt DP, Klunk WE, et al. Using a reference tissue model with spatial constraint to quantify [11C]Pittsburgh compound B PET for early diagnosis of Alzheimer’s disease. Neuroimage. 2007;36:298–312.PubMedCrossRefGoogle Scholar
  21. 21.
    Bacskai BJ, Frosch MP, Freeman SH, Raymond SB, Augustinack JC, Johnson KA, et al. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol. 2007;64:431–4.PubMedCrossRefGoogle Scholar
  22. 22.
    Mathis CA, Lopresti B, Mason N, Price J, Flatt N, Bi W, et al. Comparison of the amyloid imaging agents [F-18]3′-F-PIB and [C-11]PIB in Alzheimer’s disease and control subjects. J Nucl Med. 2007;48:56P. (abstract).Google Scholar
  23. 23.
    Ono M, Wilson A, Nobrega J, Westaway D, Verhoeff P, Zhuang ZP, et al. 11C-labeled stilbene derivatives as Abeta-aggregate-specific PET imaging agents for Alzheimer’s disease. Nucl Med Biol. 2003;30:565–71.PubMedCrossRefGoogle Scholar
  24. 24.
    Verhoeff NP, Wilson AA, Takeshita S, Trop L, Hussey D, Singh K, et al. In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. Am J Geriatr Psychiatry. 2004;12:584–95.PubMedGoogle Scholar
  25. 25.
    Rowe C, Ng S, Mulligan R, Ackermann U, Browne W, O’Keefe G, et al. First results from human studies of a novel F-18 PET ligand for brain b-amyloid imaging. J Nucl Med. 2007;48:57P. (abstract).Google Scholar
  26. 26.
    Agdeppa ED, Kepe V, Liu J, Flores-Torres S, Satyamurthy N, Petric A, et al. Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer’s disease. J Neurosci. 2001;21:RC189.PubMedGoogle Scholar
  27. 27.
    Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry. 2002;10:24–35.PubMedGoogle Scholar
  28. 28.
    Small GW, Kepe V, Ercoli LM, Siddarth P, Bookheimer SY, Miller KJ, et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med. 2006;355:2652–6.PubMedCrossRefGoogle Scholar
  29. 29.
    Cai L, Chin FT, Pike VW, Toyama H, Liow JS, Zoghbi SS, et al. Synthesis and evaluation of two 18F-labeled 6-iodo-2-(4′-N,N-dimethylamino)phenylimidazo[1,2-a]pyridine derivatives as prospective radioligands for beta-amyloid in Alzheimer’s disease. J Med Chem. 2004;47:2208–18.PubMedCrossRefGoogle Scholar
  30. 30.
    Zhang W, Oya S, Kung MP, Hou C, Maier DL, Kung HF. F-18 stilbenes as PET imaging agents for detecting beta-amyloid plaques in the brain. J Med Chem. 2005;48:5980–8.PubMedCrossRefGoogle Scholar
  31. 31.
    Zhang W, Oya S, Kung MP, Hou C, Maier DL, Kung HF. F-18 Polyethyleneglycol stilbenes as PET imaging agents targeting Abeta aggregates in the brain. Nucl Med Biol. 2005;32:799–809.PubMedCrossRefGoogle Scholar
  32. 32.
    Stephenson KA, Chandra R, Zhuang ZP, Hou C, Oya S, Kung MP, et al. Fluoro-pegylated (FPEG) imaging agents targeting Abeta aggregates. Bioconjug Chem. 2007;18:238–46.PubMedCrossRefGoogle Scholar
  33. 33.
    Cai L, Innis RB, Pike VW. Radioligand development for PET imaging of b-amyloid (Ab)-current status. Curr Med Chem. 2007;14:19–52.PubMedCrossRefGoogle Scholar
  34. 34.
    Klunk WE, Lopresti BJ, Ikonomovic MD, Lefterov IM, Koldamova RP, Abrahamson EE, et al. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer’s disease brain but not in transgenic mouse brain. J Neurosci. 2005;25:10598–606.PubMedCrossRefGoogle Scholar
  35. 35.
    Toyama H, Ye D, Ichise M, Liow JS, Cai L, Jacobowitz D, et al. PET imaging of brain with the beta-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2005;32:593–600.PubMedCrossRefGoogle Scholar
  36. 36.
    Bacskai BJ, Hickey GA, Skoch J, Kajdasz ST, Wang Y, Huang GF, et al. Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice. Proc Natl Acad Sci USA. 2003;100:12462–7.PubMedCrossRefGoogle Scholar
  37. 37.
    Manook A, Henriksen G, Platzer S, Neff F, Huisman M, Yousefi BH, et al. Feasibility of in vivo amyloid plaque imaging in a transgenic mouse model of Alzheimer’s disease. J Nucl Med. 48:116P. (abstract).Google Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Gjermund Henriksen
    • 1
  • Behrooz H. Yousefi
    • 1
  • Alexander Drzezga
    • 1
  • Hans-Jürgen Wester
    • 1
  1. 1.Department of Nuclear Medicine, Klinikum rechts der IsarTechnische Universität MünchenMünchenGermany

Personalised recommendations